TITLE

Pharmacotherapy of Bipolar Disorder in Children and Adolescents

AUTHOR(S)
Pfeifer, Jonathan C.; Kowatch, Robert A.; DelBello, Melissa P.
PUB. DATE
July 2010
SOURCE
CNS Drugs;2010, Vol. 24 Issue 7, p575
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Child and adolescent bipolar disorder (BPD) is a serious psychiatric disorder that often causes significant impairment in functioning. Pharmacological intervention is the cornerstone of treatment for bipolar youth, although psychotherapeutic interventions may be beneficial as adjunctive treatment. Medications used for the treatment of BPD in adults are still commonly used for bipolar children and adolescents. With the recent US FDA indication of risperidone, aripiprazole, quetiapine and olanzapine for the treatment of bipolar youth, the atypical antipsychotics are rapidly becoming a first-line treatment option. However, these agents are associated with adverse effects such as increased appetite, weight gain and type II diabetes mellitus. Although several evidence-based medications are now available for the treatment of BPD in younger populations, additional studies to evaluate the short- and long-term efficacy and potential for adverse events of these and other medications are needed.
ACCESSION #
52292706

 

Related Articles

  • Weight gain and new onset diabetes associated with olanzapine and risperidone. Farwell, Wildon R.; Stump, Timothy E.; Wang, Jane; Tafesse, Eskinder; L'Italien, Gilbert; Tierney, William M. // JGIM: Journal of General Internal Medicine;Dec2004, Vol. 19 Issue 12, p1200 

    Objective: To assess whether newer antipsychotic medications are associated with weight gain and development of diabetes.Design: Retrospective cohort study.Setting: Data from a comprehensive electronic medical record serving an urban public hospital and a...

  • Risperidone treatment of bipolar disorder. McIntyre, Roger; Hasey, Gary; Patelis-Siotis, Irene; Jones, Barry D.; McIntyre, R; Young, L T; Hasey, G; Patelis-Siotis, I; Jones, B D // Canadian Journal of Psychiatry;Feb1997, Vol. 42 Issue 1, p88 

    A letter to the editor is presented about a study on whether risperidone treatment can reduce mood symptoms in patients with bipolar disorder.

  • Rabbit syndrome induced by combined lithium and risperidone. Mendhekar, D. N. // Canadian Journal of Psychiatry;May2005, Vol. 50 Issue 6, p369 

    Presents a letter to the editor regarding a case of rabbit syndrome induced by combined Lithium and Risperidome, published in the May 2005 issue of the "Canadian Journal of Psychiatry."

  • Risperidone can treat psychotic mania.  // Behavioral Health Treatment;Aug96, Vol. 1 Issue 2, p8 

    Reports on the results of a study which showed that the antipsychotic risperidone also works for acute mania with psychotic features. Minimum scores; Percentages in improvement.

  • The potential role of appetite in predicting weight changes during treatment with olanzapine. Case, Michael; Treuer, Tamas; Karagianis, Jamie; Hoffmann, Vicki Poole // BMC Psychiatry;2010, Vol. 10, p72 

    Background: Clinically significant weight gain has been reported during treatment with atypical antipsychotics. It has been suggested that weight changes in patients treated with olanzapine may be associated with increased appetite. Methods: Data were used from adult patients for whom both...

  • Ergenlik Döneminde BaÅŸlayan Bipolar Bozukluklu Ä°ki Olguda Uzun Süreli Olanzapin Kullanımı. Gencer, Öziem; Miral, Süoha; Güvenir, Taner // Klinik Psikofarmakoloji Bulteni;Sep2004, Vol. 14 Issue 3, p154 

    Typical and atypical antipsychotics, mood stabilizers and antidepressants have been used in the treatment of bipolar disorder. Olanzapine, an atypical antipsychotic drug with serotonin-dopamine antagonism, has been used in the treatment of schizophrenia and bipolar disorder. The long-term...

  • Spotlight on Olanzapine/Fluoxetine in Acute Bipolar Depression. Deeks, Emma D.; Keating, Gillian M. // CNS Drugs;2008, Vol. 22 Issue 9, p793 

    Olanzapine/fluoxetine (Symbyax®) is an oral once-daily fixed-dose combination of the atypical antipsychotic olanzapine and the SSRI fluoxetine that is approved in the US for the treatment of depressive episodes associated with bipolar disorder in adults. Combination therapy with olanzapine...

  • Weight Gain and Changes in Metabolic Variables following Olanzapine Treatment in Schizophrenia and Bipolar Disorder. Citrome, Leslie; Holt, Richard I. G.; Walker, Daniel J.; Hoffmann, Vicki Poole // Clinical Drug Investigation;2011, Vol. 31 Issue 7, p455 

    Antipsychotic therapy forms the cornerstone of treatment for people with severe mental illness. Second-generation (atypical) antipsychotics are associated with a significantly lower incidence of extrapyramidal symptoms than the typical, first-generation agents; however, changes in metabolic...

  • Serum ghrelin concentrations in patients receiving olanzapine or risperidone. Togo, Takashi; Hasegawa, Koichi; Miura, Satoshi; Hosojima, Hideki; Kojima, Katsuo; Shoji, Mika; Kase, Akihiko; Uchikado, Hirotake; Iseki, Eizo; Kosaka, Kenji // Psychopharmacology;2004, Vol. 172 Issue 2, p230 

    Rationale. Although enhanced appetite and weight gain are potential side effects of treatment with antipsychotic agents, particularly olanzapine and clozapine, the mechanism is poorly understood. Objectives. To test the hypothesis that ghrelin, a gastrointestinal hormone that enhances appetite,...

Share

Read the Article

Courtesy of

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics